Menopause
Conference Coverage
No signal for CV, breast effects with bioidentical vaginal estrogen for dyspareunia
Low-dose vaginal softgel is approved for treating moderate to severe dyspareunia associated with menopause.
Conference Coverage
With more mindfulness, menopausal symptoms wane
Women in midlife with the most stress had the most benefit from mindfulness.
Expert Commentary
New and promising GSM treatments, more clinical takeaways from NAMS 2018
Dr. Richard-Davis served as the Scientific Program Chair of the 2018 NAMS Meeting. In this audiocast she highlights several clinical takeaways...
Expert Commentary
What works best for genitourinary syndrome of menopause: vaginal estrogen, vaginal laser, or combined laser and estrogen therapy?
There are not enough data to recommend laser therapy over the gold standard, transvaginal estrogen, for treating symptoms of the...
Conference Coverage
For dyspareunia, intravaginal prasterone may work best soon after menopause
Age and previous hormone replacement therapy did not influence prasterone’s efficacy in treating dyspareunia.
Clinical Review
2018 Update on menopause
Coverage and expert comment on new insights on HT and Alzheimer disease risk, HT route and sexuality outcomes, mortality in WHI participants, and...
News
No falls, fractures, or bone density benefits from vitamin D supplements
Vitamin D supplementation does not appear to reduce the risk of falls or fracture or to improve bone mineral density.
Expert Commentary
Managing menopausal symptoms in breast cancer survivors
What types of menopausal symptoms are breast cancer survivors faced with, and following breast cancer, what treatments should clinicians...
Conference Coverage
Zoledronate reduces fracture risk in elderly women with osteopenia
Women with osteopenia who received intravenous zoledronate had a significantly lower risk of fractures.
Expert Commentary
How to assess a patient for a bisphosphonate drug holiday
Dr. McClung also discusses long-term denosumab therapy
News
Guidelines released for perimenopausal depression
The risk of perimenopausal depression is estimated to be 45%-68%.